Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume
Recruiting
Observational Study
Moderate or Severe Mitral Regurgitation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 95
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- Germans Trias i Pujol Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is demonstrate that a novel artificial intelligence based software for the quantification of the mitral regurgitation on 3-dimensional transesophageal echocardiography (3D CFQ) is more reproducible and accurate than the conventional assessment of mitral regurgitation performed with 2-dimensional echocardiography. The main question aims to answer is to demonstra…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with at least moderate mitral regurgitation of any etiology
* Patients with good transesophageal echocardiography image quality
Exclusion Criteria:
* Patients with prior transcatheter or surgical mitral valve intervention
* Patients with contraindications for transe…
Contacts
Victoria Delgado, Head of Cardiovascular Imaging department, MD, PhD
+34 93 497 89 15
cardiologia.germanstrias@gencat.cat
CONTACT